<DOC>
	<DOCNO>NCT01958372</DOCNO>
	<brief_summary>This phase I trial study side effect soy isoflavones give together radiation therapy chemotherapy treat patient stage IIIA-IIIB non-small cell lung cancer . Radiation therapy use high energy x ray kill tumor cell . Drugs use chemotherapy , cisplatin , pemetrexed sodium , etoposide , work different way stop growth tumor cell , either kill cell stop dividing . Soy isoflavones may help radiation therapy , cisplatin , pemetrexed sodium , etoposide work well make tumor cell sensitive drug . Soy isoflavones may also protect normal cell side effect radiation therapy chemotherapy .</brief_summary>
	<brief_title>Radiation Therapy , Chemotherapy , Soy Isoflavones Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety add oral soy isoflavone concurrent chemotherapy radiotherapy treatment patient unresectable stage III non-small cell lung cancer ( NSCLC ) . OUTLINE : Patients assign 1 2 treatment group . GROUP I ( SQUAMOUS CELL HISTOLOGY ) : Patients receive etoposide intravenously ( IV ) 1 hour day 1-5 29-33 , cisplatin IV 1 hour day 1 , 8 , 29 , 36 , undergo radiation therapy ( RT ) 5 day week 6.6 week . Within 48 hour initiate treatment , patient receive soy isoflavones orally ( PO ) daily day 1-90 . GROUP II ( NON-SQUAMOUS CELL HISTOLOGY ) : Patients receive pemetrexed disodium IV 10 minute day 1 , 22 , 43 cisplatin IV 1 hour day 1 , 22 , 43 . Patients also undergo RT receive soy isoflavones Group I . After completion study treatment , patient follow 4 week every 4 month 1 year , every 6 month 1 year , yearly thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis stage III nonsmall cell lung cancer ; patient need meet following criterion stage IIIA IIIB diagnosis : IIIA Histologic cytologic diagnosis ipsilateral mediastinal lymph node involvement , Tumors great 7 cm chest wall invasion , involvement one follow diaphragm , phrenic nerve , mediastinal pleura parietal pericardium hilar mediastinal lymph node involvement More one mediastinal lymph node enlarge compute tomography ( CT ) scan lymph node positive positron emission tomography ( PET ) scan Paralyzed leave vocal cord separate lung primary distinct aortopulmonary lymph node CT scan IIIB Histologic cytologic diagnosis N3 lymph node involvement ; Enlarged N3 lymph node CT scan positive PET scan well ; patient must extension lymph node involvement cervical lymph node supraclavicular lymph node ; Right side primary leave vocal cord paralysis ; Evidence tumor extension mediastinum and/or mediastinal structure either time mediastinoscopy , bronchoscopy CT scan Patients nodule lung area involvement Patients prior surgically resected stage I NSCLC receive adjuvant therapy , stage IIIA B NSCLC eligible Southwestern Oncology Group ( SWOG ) performance status 0 1 Absolute neutrophil count &gt; 1.5 x 10^9/L Platelet count &gt; 100,000 x 10^9/L Serum creatinine = &lt; 1.5 time institutional upper limit normal ( ULN ) Calculated creatinine clearance ( CockcroftGault formula ) &gt; = 45mL/min Serum bilirubin &gt; ULN Transaminases ( serum glutamic oxaloacetic transaminase [ SGOT ] and/or serum glutamate pyruvate transaminase [ SGPT ] ) &gt; 1.5 time institutional ULN Alkaline phosphatase &gt; = 2.5 time ULN Forced expiratory volume one second ( FEV1 ) &gt; = 1 liter diffusion capacity carbon monoxide ( DLCO ) &gt; = 40 % predict Patient undergo brain imaging ( CT scan magnetic resonance image [ MRI ] ) rule brain metastasis Signed informed consent detail investigational nature study accord institutional federal guideline Registered Clinical Trials Office Karmanos Cancer Institute/Wayne State University Prior chemotherapy , radiation malignancy receive thoracic radiotherapy Patients concurrent malignancy ; patient prior concurrent malignancy allow long treat physician considers unlikely impact clinical outcome patient Patients peripheral neuropathy &gt; 2 Serious medical illness include limited uncontrolled congestive heart failure , uncontrolled angina , myocardial infarction cerebrovascular event 6 month registration , history chronic active hepatitis history human immunodeficiency virus ( HIV ) active bacterial infection eligible Inability unwillingness take folic acid vitamin B12 dexamethasone Pregnant lactate woman ; premenopausal perimenopausal woman urine test pregnancy within week start therapy ; patient child bear potential agree use effective contraceptive method Patients participate therapeutic investigational study take part study Patients warfarin allow study ; patient low molecular heparin anti direct factor Xa inhibitor ( Xa ) drug allow Patients soy allergy exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>